While the markets reacted badly to the news Newron Pharmaceuticals SPA is to delay starting the pivotal program for its closely watched schizophrenia therapy evenamide, the Italian-headquartered drugmaker is confident that concerns raised by the US Food and Drug Administration over central nervous system events seen in animals can be allayed quickly.
No Panic At Newron Over Delayed Schizophrenia Drug Trial
Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.
More from Neurological
More from Therapy Areas
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.